AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · New York

A09583

Establishes a research grant program to fund clinical trials of ibogaine for the treatment of veterans for post-traumatic stress disorder; creates a fund to provide monies for the research grant program.

Status

Pending

2026 Session

IntroducedJan 21, 2026 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Robert Smullen (Republican)
Type: Clinical Research
Substances: Ibogaine

Official text

Summary (from PoliPsy)

Establishes a research grant program to fund clinical trials of ibogaine for the treatment of veterans for post-traumatic stress disorder; creates a fund to provide monies for the research grant program.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: nysenate.gov

Legislative history

January 21, 2026
Referred
January 21, 2026
Referred
January 21, 2026
Introduced

Loading bill…